Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017:2017:1683060.
doi: 10.1155/2017/1683060. Epub 2017 Dec 3.

Metronomic Chemotherapy in Triple-Negative Metastatic Breast Cancer: The Future Is Now?

M E Cazzaniga  1   2 , L Cortesi  3 , A Ferzi  4 , L Scaltriti  5 , F Cicchiello  2 , M Ciccarese  6 , S Della Torre  7 , F Villa  8 , M Giordano  9 , C Verusio  10 , M Nicolini  11 , A R Gambaro  12 , L Zanlorenzi  13 , E Biraghi  14 , E Casini  2 , L Legramandi  15 , E Rulli  15
Affiliations
Review

Metronomic Chemotherapy in Triple-Negative Metastatic Breast Cancer: The Future Is Now?

M E Cazzaniga et al. Int J Breast Cancer. 2017.

Abstract

Triple-negative breast cancer (TNBC) shows a very bad prognosis, even in early stages of disease. Metronomic chemotherapy refers to the minimum biologically effective dose of a chemotherapy agent given as a continuous dosing regimen with no prolonged drug-free breaks that leads to antitumor activity. In the present article, we review preclinical and clinical data of metronomic administration of chemotherapy agents with or without biological agents in TNBC cell lines and patients, contextually reporting data from the VICTOR-2 study in the subgroup of patients with TNBC, in order to stimulate new ideas for the design of clinical trials in this subset of patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Consort diagram VICTOR 2 trial.
See this image and copyright information in PMC

References

    1. André F., Zielinski C. C. Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. Annals of Oncology. 2012;23(6):vi46–vi51. doi: 10.1093/annonc/mds195.mds195 - DOI - PubMed
    1. Bauer K. R., Brown M., Cress R. D., Parise C. A., Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype. Cancer. 2007;109(9):1721–1728. doi: 10.1002/cncr.22618. - DOI - PubMed
    1. Di Desidero T., Kerbel R. S., Bocci G. Metronomic chemotherapy for triple negative breast cancer? AGING. 2016;8(4):573–574. doi: 10.18632/aging.100947. - DOI - PMC - PubMed
    1. Kareva I., Waxman D. J., Klement G. L. Metronomic chemotherapy: An attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance. Cancer Letters. 2015;358(2):100–106. doi: 10.1016/j.canlet.2014.12.039. - DOI - PMC - PubMed
    1. Colleoni M., Gray K. P., Gelber S., et al. Low-dose oral cyclophosphamide and methotrexate maintenance for hormone receptor-negative early breast cancer: International Breast Cancer Study Group Trial 22-00. Journal of Clinical Oncology. 2016;34(28):3400–3408. doi: 10.1200/JCO.2015.65.6595. - DOI - PMC - PubMed

LinkOut - more resources